Information  X 
Enter a valid email address
  Print          More announcements

Friday 01 October, 2021

Morgan Stanley Smith

Form 8.3 - STRONGBRIDGE BIOPHARMA PLC

RNS Number : 7327N
Morgan Stanley Smith Barney LLC
01 October 2021
 

 

 

 

FORM   8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.  KEY   INFORMATION

 

Nameofpersondealing (Note 1)

Morgan Stanley Smith Barney LLC

Companydealtin

STRONGBRIDGE BIOPHARMA PLC

Classofrelevantsecuritytowhichthe dealingsbeingdisclosedrelate (Note2)

$0.01 ORDINARY SHARES

Date of dealing

30 September 2021

 

2.  INTERESTS AND SHORT POSITIONS

 

  (a)   Interests and short positions (following dealing) in the class of relevant security

  dealt in ( Note 3)

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1)Relevantsecurities

1,803,918

2.66

  0

    0.00

(2)Derivatives (other than options)

0

0.00

  0

  0.00

(3)Options and agreements to purchase/sell

0

0.00

  0

  0.00

Total

1,803,918

2.66

  0

  0.00

                 

 

 

(b)  Interests and short positions in relevant securities of the company, other than the  

  class dealt in ( Note 3 )

Class of relevant security:

Long

Short

 

Number

 

(%)

Number

 

(%)

(1)Relevantsecurities

0

0.00

  0

    0.00

(2)Derivatives (other than options)

0

0.00

  0

  0.00

(3)Options and agreements to purchase/sell

0

0.00

  0

  0.00

Total

0

0.00

  0

  0.00

                 

 


 

 

 

 

 

 

 

1.  DEALINGS  (Note   4)

(a)  Purchases and sales

 

Purchase/sale

Number of relevant securities

Price per unit (Note 5)

SALE

285

2.0100 USD

SALE

13

2.0427 USD

 

 

(b)  Derivatives transactions (other than options transactions)

 

Productname,

e.g. CFD

Natureoftransaction

(Note 6)

Numberofrelevantsecurities

(Note 7)

Priceperunit

(Note 5)

N/A

N/A

N/A

N/A

 

 

(c)  Options transactions in respect of existing relevant securities

 

 

(i)  Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varyingetc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, Europeanetc.

Expiry date

Option money paid/received perunit (Note 5)

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

 

(ii)  Exercising

 

Productname,

e.g. call option

Numberofsecurities

Exercisepriceper unit (Note 5)

N/A

N/A

N/A

 

 

(d)  Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

N/A

N/A

N/A

 

2.  OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Fulldetailsofanyagreement,arrangementorunderstandingbetweenthepersondisclosing andanyotherpersonrelatingtothevotingrightsofanyrelevantsecuritiesunderanyoption referredtoonthisformorrelatingtothevotingrightsorfutureacquisitionordisposalofanyrelevantsecuritiestowhichanyderivativereferredtoonthisformisreferenced.Ifnone,this shouldbestated.

 

 

NONE

 

 

 

 

 

 

Is a Supplemental Form 8 attached?  (Note   9)     NO

 

Dateofdisclosure

01 October 2021

Contact name

Craig Horsley

Telephone number

+44 141 245-7736

If aconnectedEFM,nameofofferee/offerorwithwhichconnected

N/A

If aconnectedEFM,statenatureofconnection (Note 10)

N/A

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ISEMZMGGLMKGMZG

a d v e r t i s e m e n t